Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Gastroenterology
    • Pegbelfermin an...

    Pegbelfermin an effective medicine for Non-Alcoholic Fatty Liver disease, shows Trial

    Written by Medha Baranwal Baranwal Published On 2019-01-07T19:25:16+05:30  |  Updated On 7 Jan 2019 7:25 PM IST
    Pegbelfermin an effective medicine for Non-Alcoholic Fatty Liver disease, shows Trial

    USA: Treatment with Pegbelfermin significantly reduced hepatic fat fraction in non-alcoholic steatohepatitis (NASH) patients, according to a phase 2a trial published in the journal Lancet. No medicines have been approved to treat NAFLD and NASH till now.


    Non-alcoholic steatohepatitis is a form of fatty liver disease that is characterized by hepatic necroinflammation, progression of fibrosis, and a strong association with metabolic syndrome and is increasing as a cause of morbidity and mortality.


    Pegbelfermin, a PEGylated human fibroblast growth factor 21 (FGF21) analog, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. In this phase 2a study, Edgar D Charles, Bristol-Myers Squibb, Lawrenceville, NJ, USA, and colleagues aimed to evaluate the safety and efficacy of pegbelfermin in 75 NASH patients: 25 assigned to pegbelfermin 10 mg once a day, 24 assigned to pegbelfermin 20 mg once a week and 26 assigned to placebo.


    Study enrollment was ended prior to enrolling the planned sample size of 30 patients per group because of a significant effect of pegbelfermin on hepatic fat fraction during the interim analysis at treatment week 8.


    Also Read: Fatty diet linked to serious type of liver disease, warns Study

    Key Findings:

    • After 16 weeks of treatment, mean hepatic fat fraction dropped by 6.8% with pegbelfermin once daily, by 5.2% with pegbelfermin once weekly and by 1.3% compared with placebo.

    • Most patients treated with pegbelfermin developed anti-pegbelfermin and anti-FGF21 antibodies, but titers were generally low and not associated with immune-related adverse events.

    • Pegbelfermin treatment was also associated with significant improvements in adiponectin concentration and with significant decreases in PRO-C3, a biomarker of fibrosis.

    • Mean concentrations of alanine aminotransferase and aspartate aminotransferase decreased with pegbelfermin treatment, as did mean liver stiffness as measured by magnetic resonance elastography (MRE).


    Also Read: MRI to quantifies liver response in nonalcoholic steatohepatitis patients

    "Treatment with subcutaneously administered pegbelfermin for 16 weeks was generally well tolerated and significantly reduced hepatic fat fraction in patients with non-alcoholic steatohepatitis. Further study of pegbelfermin is warranted in patients with non-alcoholic steatohepatitis." concluded the authors.


    For further reference log on to https://doi.org/10.1016/S0140-6736(18)31785-9
    ChancesdecreasesEdgar D CharlesFatty liverfibrosishepatic fat fractioninflammationliver diseaseliver fibrosisNASHNon Alcoholic Fatty LiverNon-alcoholic steatohepatitisPegbelfermin
    Source : With inputs from Lancet

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok